Biotech News

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

Phathom Pharmaceuticals (PHAT)Phathom Pharmaceuticals2026-06-25 13:46 ESTFinancing

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today the pricing of an underwritten public offering of 6,875,000

Open original release

Related news

PHATPhathom Pharmaceuticals2026-06-25 13:46 EST

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

PHATPhathom Pharmaceuticals2026-06-25 13:46 EST

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

PHATPhathom Pharmaceuticals2026-06-25 13:46 EST

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

PHATPhathom Pharmaceuticals2026-06-25 13:46 EST

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

PHATPhathom Pharmaceuticals2026-06-25 13:46 EST

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

PHATPhathom Pharmaceuticals2026-06-25 13:46 EST

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance (Corrected)

PHATPhathom Pharmaceuticals2026-06-25 13:46 EST

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

PHATPhathom Pharmaceuticals2026-06-25 13:46 EST

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

PHATPhathom Pharmaceuticals2026-06-25 13:46 EST

Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

PHATPhathom Pharmaceuticals2026-06-25 13:46 EST

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

View all latest news

Phathom Pharmaceuticals

Phathom Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

PHATPhathom Pharmaceuticals2026-06-26 12:07 EST

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

PHATPhathom Pharmaceuticals2026-06-26 12:07 EST

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

PHATPhathom Pharmaceuticals2026-06-26 12:07 EST

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

PHATPhathom Pharmaceuticals2026-06-26 12:07 EST

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

PHATPhathom Pharmaceuticals2026-06-26 12:07 EST

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States